Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Venetoclax save search
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: 3.82%
H: 0.0%
C: -5.15%
rezlidhia publication aml leukemia
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Published: 2024-04-04 (Crawled : 12:00) - prnewswire.com
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: 3.82%
H: 0.0%
C: -5.15%
rezlidhia publication aml leukemia
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
MEIP | $3.31 -1.78% -1.81% 5K
|
Health Technology
|
| O: -1.08%
H: 1.9%
C: 0.78%
pharma update leukemia study
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
VINC | $0.955 9.9% 9.01% 410K
|
|
| O: 38.56%
H: 4.59%
C: -16.82%
pharma
Pivekimab Sunirine, a CD123 CD123-Targeting Antibody Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
Published: 2023-12-10 (Crawled : 00:00) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 2.32%
C: 1.37%
cd123 antibody leukemia
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Published: 2023-12-06 (Crawled : 15:30) - biospace.com/
SYRS | $5.17 3.61% 3.48% 170K
|
Health Technology
|
| O: 2.13%
H: 61.11%
C: 39.58%
trial
AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
Published: 2023-06-09 (Crawled : 07:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.06%
H: 1.18%
C: 0.45%
venclyxto leukemia show
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Published: 2023-06-07 (Crawled : 12:00) - prnewswire.com
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: 0.66%
H: 5.26%
C: 2.63%
rezlidhia presentation aml
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
Published: 2023-05-23 (Crawled : 13:00) - biospace.com/
MEIP | $3.31 -1.78% -1.81% 5K
|
Health Technology
|
| O: 0.14%
H: 8.44%
C: 0.54%
pharma update ongoing leukemia study
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
Published: 2022-12-12 (Crawled : 15:20) - globenewswire.com
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 0.93%
H: 10.14%
C: 4.15%
aspen-05 leukemia study acute myeloid leukemia
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
Published: 2022-12-12 (Crawled : 14:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: -1.67%
H: 1.7%
C: 0.0%
tp53 treatment aml trial presentation
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Published: 2022-12-12 (Crawled : 13:00) - biospace.com/
APVO | $0.7475 5.28% 5.02% 350K
|
Health Technology
|
| O: 98.09%
H: 4.65%
C: -43.17%
apvo436 treatment leukemia trial acute myeloid leukemia aml phase 2b
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
imbruvica treatment glow leukemia response plus results study
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-11-30 (Crawled : 23:00) - biospace.com/
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: 0.0%
leukemia study acute myeloid leukemia phase 1
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
Published: 2022-04-12 (Crawled : 12:20) - biospace.com/
CYCC | $1.805 3.14% 3.05% 28K
|
Health Technology
|
| O: 8.46%
H: 0.0%
C: -20.34%
leukemia
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
Published: 2022-04-11 (Crawled : 12:20) - globenewswire.com
SLS | $1.615 4.87% 4.64% 2M
|
Health Technology
|
| O: -4.14%
H: 4.61%
C: 0.29%
gfh009 ongoing leukemia license phase 1 acute myeloid leukemia
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: -4.84%
H: 2.03%
C: -7.27%
tp53 als trial phase 1 aml
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
KURA | News | $18.74 3.02% 2.93% 1M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
ko-539 preclinical pre-clinical
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Published: 2021-12-12 (Crawled : 16:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
imgn632 myeloid leukemia phase 1b leukemia phase 1 positive acute myeloid leukemia phase 2b
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
Published: 2021-12-11 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
imbruvica treatment leukemia disease phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.